Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Chromatin Plasticity Characterizes the Embryonic Stem Cell Nucleus

By LabMedica International staff writers
Posted on 02 Aug 2012
A recent paper presented new insights into the mechanisms that control chromatin plasticity in human embryonic stem cells and that allow these cells to differentiate in to many different types of tissue.

Investigators at the Hebrew University of Jerusalem (Israel) employed molecular, microscopic, and genomic approaches to compare the nature of chromatin (DNA, RNA, and protein) in embryonic stem cells (ESCs) to that found in mature, differentiated cells.

They reported in the June 19, 2012, issue of the journal Nature Communications that the use of epigenetic drugs and mutant ESCs lacking various chromatin proteins revealed that histone acetylation, G9a-mediated histone H3 lysine 9 (H3K9) methylation, and lamin A expression, all affected chromatin protein dynamics. More...


Histone acetylation controlled, almost exclusively, euchromatin protein dynamics. Euchromatin comprises the most active portion of the genome within the cell nucleus. It is a lightly packed form of chromatin that is rich in gene concentration, and is often under active transcription.

Lamin A expression regulates heterochromatin protein dynamics. Heterochromatin is tightly coiled chromosomal material that stains deeply during interphase and is believed to be genetically inactive. In differentiated cells, lamin A binds compacted domains of chromatin and anchors them to the cell’s nuclear envelope. Lamin A was not found in ESCs, which seems to generate a more dynamic chromatin state in the ESC nucleus.

G9a, the histone-lysine N-methyltransferase also known as H3 lysine-9 specific 3, regulates both euchromatin and heterochromatin protein dynamics.

In contrast, the investigators found that DNA methylation and nucleosome repeat length had little or no effect on chromatin-binding protein dynamics in ESCs. Altered chromatin dynamics associated with perturbed ESC differentiation.

“If we can apply this new understanding about the mechanisms that give embryonic stem cells their plasticity, then we can increase or decrease the dynamics of the proteins that bind DNA and thereby increase or decrease the cells’ differentiation potential,” said senior author Dr. Eran Meshorer, professor of genetics at the Hebrew University of Jerusalem. “This could expedite the use of embryonic stem cells in cell therapy and regenerative medicine, by enabling the creation of cells in the laboratory which could be implanted in humans to cure diseases characterized by cell death, such as Alzheimer's, Parkinson's, diabetes, and other degenerative diseases.”

Related Links:

Hebrew University of Jerusalem




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Manual Pipetting Aid
Pipette Controllers macro
Hematology Consumables
Bioblood Devices
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Graphical abstract (Pola, I., Akinyemi, T., Tan, K. et al. Nature Communications(2026). https://doi.org/10.1038/s41467-026-74971-4)

Blood Biomarker Study Reveals Population-Specific Differences in Alzheimer’s Disease

Blood-based biomarkers are emerging as tools for detecting Alzheimer’s disease–related changes without relying on advanced brain imaging or cerebrospinal fluid (CSF) analysis. However, much of the foundational... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.